中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 6
Jun.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(6): 1226-1230

Value of skeletal muscle index combined with interleukin-6 and activin A in predicting early-stage pancreatic cancer cachexia

DOI: 10.12449/JCH240624

  • Department of Hepatobiliary Surgery，Hebei Medical University Fourth Hospital，Shijiazhuang 050011，China

Research funding:

Hebei Medical Science Research Project (20240222)

More Information
  • Corresponding author: FENG Ningning， syanshuxuesan@163.com （ORCID： 0009-0002-8784-3918）
  • Received Date: 2024-02-20
  • Accepted Date: 2024-03-25
  • Published Date: 2024-06-25
    Abstract
  •   Objective  To investigate the value of L3 skeletal muscle index （L3-SMI） combined with interleukin-6 （IL-6） and activin A in predicting early-stage pancreatic cancer cachexia.  Methods  A total of 74 patients with pancreatic cancer who were diagnosed in Hebei Medical University Forth Hospital from July 2020 to July 2023 were enrolled， and according to the presence or absence of cachexia after admission， the patient were divided into cachexia group with 58 patients and non-cachexia group with 16 patients. The levels of L3-SMI， IL-6， and activin A were observed within 48 hours after admission. The independent-samples t test was used for comparison of normally distributed continuous data between groups， and the chi-square test was used for comparison of categorical data between groups. A multivariate Logistic regression analysis was used to investigate the influencing factors for pancreatic cancer cachexia； the receiver operating characteristic （ROC） curve was used to analyze the value of L3-SMI， IL-6， and activin A alone or in combination in predicting pancreatic cancer cachexia， and the Z test was used for comparison of the area under the ROC curve （AUC）.  Results  Compared with the non-cachexia group， the cachexia group had a significantly higher level of L3-SMI and significantly lower serum levels of IL-6 and activin A （t=8.649， 3.049， and 8.100， all P<0.05）. The multivariate logistic analysis showed that L3-SMI （odds ratio ［OR］=0.266， 95% confidence interval ［CI］： 0.103‍ ‍—‍ ‍0.683， P<0.05）， serum IL-6 （OR=4.158， 95%CI： 1.368‍ ‍—‍ ‍12.333， P<0.05）， and activin A （OR=5.124， 95%CI： 1.550‍ ‍—‍ ‍16.939， P<0.05） were influencing factors for pancreatic cancer cachexia. L3-SMI， IL-6， and activin A alone had a significantly lower AUC than the combination of the three indicators in predicting pancreatic cancer cachexia （0.851/0.752/0.791 vs 0.946， Z=-2.841， -2.552， and -2.647， all P<0.001）， and the combination of the three indicators had the highest sensitivity （90.9%）， specificity （87.8%） and Youden index （0.788）.  Conclusion  L3-SMI combined with serum IL-6 and activin A has a good value in predicting early-stage pancreatic cancer cachexia.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    ZHAN HX, LI YZ, HU SY. Tissue wasting and perioperative treatment strategies of pancreatic cancer patients[J]. Chin J Dig Surg, 2021, 20( 4): 407- 413. DOI: 10.3760/cma.j.cn115610-20210217-00079.

    展翰翔, 李永政, 胡三元. 胰腺癌病人组织消耗与围术期处理策略[J]. 中华消化外科杂志, 2021, 20( 4): 407- 413. DOI: 10.3760/cma.j.cn115610-20210217-00079.
    [2]
    ROBERTS DA, WATSON E, MACDONALD C, et al. Management of pain and Cachexia in pancreatic cancer: Protocol for two systematic reviews, network meta-analysis, surveys, and focus groups[J]. JMIR Res Protoc, 2023, 12: e46335. DOI: 10.2196/46335.
    [3]
    FAN M, GU XF, ZHANG WL, et al. Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL-6 and tumour-derived extracellular vesicles[J]. J Cachexia Sarcopenia Muscle, 2022, 13( 6): 2724- 2739. DOI: 10.1002/jcsm.13079.
    [4]
    DAITOKU N, MIYAMOTO Y, HIYOSHI Y, et al. Activin A promotes cell proliferation, invasion and migration and predicts poor prognosis in patients with colorectal cancer[J]. Oncol Rep, 2022, 47( 6): 107. DOI: 10.3892/or.2022.8318.
    [5]
    Pancreatic Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer(2018 version)[J]. J Clin Hepatol, 2018, 34( 10): 2109- 2120. DOI: 10.3969/j.issn.1001-5256.2018.10.011.

    中国抗癌协会胰腺癌专业委员会. 胰腺癌综合诊治指南(2018版)[J]. 临床肝胆病杂志, 2018, 34( 10): 2109- 2120. DOI: 10.3969/j.issn.1001-5256.2018.10.011.
    [6]
    BABIC A, ROSENTHAL MH, SUNDARESAN TK, et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer[J]. Nat Commun, 2023, 14( 1): 4317. DOI: 10.1038/s41467-023-40024-3.
    [7]
    SUN H, XU H, LU YY, et al. Clinical value of nutritional risk screening tools in identifying sarcopenia in patients with gastric cancer[J]. J Clin Med Pract, 2023, 27( 2): 78- 83. DOI: 10.7619/jcmp.20223111.

    孙慧, 徐慧, 陆滢滢, 等. 营养风险筛查工具识别胃癌患者肌减少症的临床价值[J]. 实用临床医药杂志, 2023, 27( 2): 78- 83. DOI: 10.7619/jcmp.20223111.
    [8]
    MARTIN A, FREYSSENET D. Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: Lessons from human and animal studies[J]. J Cachexia Sarcopenia Muscle, 2021, 12( 2): 252- 273. DOI: 10.1002/jcsm.12678.
    [9]
    ZENG X, SHI ZW, YU JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: A multicentre study in China[J]. J Cachexia Sarcopenia Muscle, 2021, 12( 6): 1948- 1958. DOI: 10.1002/jcsm.12797.
    [10]
    WAKABAYASHI H, ARAI H, INUI A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: Facts and numbers[J]. J Cachexia Sarcopenia Muscle, 2021, 12( 1): 14- 16. DOI: 10.1002/jcsm.12675.
    [11]
    YU ZL, SHANG NJ. Correlation between intramuscular fatty infiltration and sarcopenia after radical gastrectomy in elderly patients with gastric cancer[J]. J Mod Oncol, 2022, 30( 19): 3539- 3543. DOI: 10.3969/j.issn.1672-4992.2022.19.018.

    于子玲, 尚乃舰. 肌内脂肪浸润与老年胃癌根治术后肌少症的相关性[J]. 现代肿瘤医学, 2022, 30( 19): 3539- 3543. DOI: 10.3969/j.issn.1672-4992.2022.19.018.
    [12]
    ZHAO ZY, ZHANG YY, ZHAN XB. The value of skeletal muscle index of the third lumbar vertebra in nutritional risk assessment and prognosis of patients with advanced gastric cancer[J]. Mod Med J, 2022, 50( 11): 1371- 1376. DOI: 10.3969/j.issn.1671-7562.2022.11.003.

    赵志越, 张颖一, 湛先保. 第三腰椎骨骼肌指数在晚期胃癌患者营养风险评估及预后中的价值[J]. 现代医学, 2022, 50( 11): 1371- 1376. DOI: 10.3969/j.issn.1671-7562.2022.11.003.
    [13]
    POTOTSCHNIG I, FEILER U, DIWOKY C, et al. Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL/6 model of cancer-associated cachexia[J]. J Cachexia Sarcopenia Muscle, 2023, 14( 1): 93- 107. DOI: 10.1002/jcsm.13109.
    [14]
    QIU ZL, WO D, ZHONG XM, et al. Babao Dan alleviates cancer Cachexia in mice via inhibiting IL-6/STAT3 signaling pathway[J]. Integr Cancer Ther, 2023, 22: 15347354231168369. DOI: 10.1177/15347354231168369.
    [15]
    SHUKLA SK, MARKOV SD, ATTRI KS, et al. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia[J]. Cancer Lett, 2020, 484: 29- 39. DOI: 10.1016/j.canlet.2020.04.017.
    [16]
    XU PC, YOU M, YU SY, et al. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: The role of activin A signaling[J]. Sci Rep, 2022, 12( 1): 1659. DOI: 10.1038/s41598-022-05660-7.
    [17]
    PINJUSIC K, AMBROSINI G, LOURENCO J, et al. Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING[J]. Front Immunol, 2024, 14: 1335207. DOI: 10.3389/fimmu.2023.1335207.
    [18]
    JIA SQ, ZHOU QY, LIU HM, et al. The mortality trend of digestive tract malignant tumor in China from 2004 to 2018[J]. Chin J Dis Contr Prev, 2021, 25( 9): 1020- 1025. DOI: 10.16462/j.cnki.zhjbkz.2021.09.006.

    贾善群, 周乾宇, 刘慧敏, 等. 2004―2018年中国消化道恶性肿瘤死亡趋势[J]. 中华疾病控制杂志, 2021, 25( 9): 1020- 1025. DOI: 10.16462/j.cnki.zhjbkz.2021.09.006.
    [19]
    CAI J, CHEN HD, LU M, et al. Trend analysis on morbidity and mortality of pancreatic cancer in China, 2005-2015[J]. Chin J Epidemiol, 2021, 42( 5): 794- 800. DOI: 10.3760/cma.j.cn112338-20201115-01328.

    蔡洁, 陈宏达, 卢明, 等. 2005—2015年中国胰腺癌发病与死亡趋势分析[J]. 中华流行病学杂志, 2021, 42( 5): 794- 800. DOI: 10.3760/cma.j.cn112338-20201115-01328.
    [20]
    WANG S, DU L, CHEN H, et al. Paracrine production of IL-6 promotes a hypercoagulable state in pancreatic cancer[J]. Am J Cancer Res, 2021, 11( 12): 5992- 6003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (37) PDF downloads(9) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return